Alector is developing latozinemab in collaboration with GSK, and the FDA granted Breakthrough Therapy designation for the drug, which targets FTD-GRN.
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alector is developing latozinemab in collaboration with GSK, and the FDA granted Breakthrough Therapy designation for the drug, which targets FTD-GRN.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Mizuho upgraded Alector on August 1, 2025, based on the anticipation of positive Phase 3 trial data for latozinemab, Alector's lead asset for FTD, expected in Q4 2025.Sub-event
FDA granted Breakthrough Therapy designation for latozinemab, developed by Alector in collaboration with GSK, for FTD-GRN.1 source
Keep exploring
The entities involved
-
GSK
British multinational pharmaceutical and biotechnology company
-
Alector (United States)
company in San Francisco, United States
Nothing else this week.
- FDA
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireAlector Reports Second Quarter 2025 Financial Results and Provides Business Update On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in F